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Q fever is a zoonotic disease of worldwide significance caused by the obligate intracellular bacterium Coxiella
burnetii. Humans with Q fever may experience an acute flu-like illness and pneumonia and/or chronic hepatitis
or endocarditis. Various markers demonstrate significant phylogenetic separation between and clustering
among isolates from acute and chronic human disease. The clinical and pathological responses to infection
with phase I C. burnetii isolates from the following four genomic groups were evaluated in immunocompetent
and immunocompromised mice and in guinea pig infection models: group I (Nine Mile, African, and Ohio),
group IV (Priscilla and P), group V (G and S), and group VI (Dugway). Isolates from all of the groups produced
disease in the SCID mouse model, and genogroup-consistent trends were noted in cytokine production in
response to infection in the immunocompetent-mouse model. Guinea pigs developed severe acute disease when
aerosol challenged with group I isolates, mild to moderate acute disease in response to group V isolates, and
no acute disease when infected with group IV and VI isolates. C. burnetii isolates have a range of disease
potentials; isolates within the same genomic group cause similar pathological responses, and there is a clear
distinction in strain virulence between these genomic groups.
Coxiella burnetii, the etiologic agent of acute and chronic Q
fever, is an obligate intracellular bacterium with worldwide
distribution and a diverse host range. Livestock serve as the
organism’s primary reservoir and may be asymptomatic carri-
ers or exhibit reproductive disorders. Ticks are important in
the maintenance of the disease in nature and have been shown
to transmit the infection transovarially (37). Humans are most
often infected through inhalation of the bacterium in fine-
particle aerosols, though transmission may also occur through
ingestion of the organism from contaminated, unpasteurized
dairy products (22, 27). Although a high percentage of infec-
tions may result in subclinical or asymptomatic infection, hu-
mans can become ill from exposure to as few as 10 organisms
(6) and may display signs of (i) an acute flu-like illness with or
without pneumonia and/or hepatitis (30, 31) or (ii) a chronic
disease manifesting most frequently as endocarditis and/or
hepatitis (40, 41).
C. burnetii isolates have been obtained from natural Q fever
infections in humans and other animals. Several theories have
been proposed to explain the dichotomy in development of
acute and chronic Q fever. Unique sequence differences be-
tween genomic groups are correlated with the clinical expres-
sion of Q fever (44). Biochemical markers have grouped C.
burnetii isolates from chronic-disease patients separately from
acute-disease/arthropod/domestic animal isolates, but whether
these groupings predict virulence potential and acute/chronic-
disease outcomes has not yet been fully resolved (20). Samuel
et al. were the first to separate these isolates and their resulting
diseases based on plasmid patterns (44). Hackstadt used vari-
ations in lipopolysaccharide (LPS) banding patterns to divide
isolates of C. burnetii into three groups, and group distinction
was noted in correlation with acute or chronic disease (16).
Hendrix et al. separated C. burnetii isolates into six genomic
groups (20). Group I to III isolates have a QpH1 plasmid and
have been isolated from ticks, acute human Q fever cases,
cow’s milk, and livestock abortions. Groups IV and V have a
QpRS plasmid or no plasmid (with plasmid-related sequences
integrated into the chromosome), respectively, and have been
associated with livestock abortions and human chronic endo-
carditis or hepatitis. Group VI isolates were collected from
wild rodents in Dugway, UT, and were infectious but avirulent
in rodent models of disease (47, 48). Jager et al. used restric-
tion fragment length polymorphism (RFLP) to differentiate 80
C. burnetii isolates and reproduced distinguishable patterns for
reference isolates in groups I, IV, V, and VI (23). More re-
cently, multiple-locus variable nucleotide tandem repeat anal-
yses (49) have validated these groupings. Infrequent-restric-
tion-site PCR of 14 livestock and tick isolates resulted in six
groups; subsequent multiple-locus variable-number tandem re-
peat analysis typing of 42 isolates revealed 36 genotypes (2).
Glazunova et al. used multispacer sequence typing to analyze
173 isolates, a majority of which were acquired from chronic-
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disease patients, and identified 30 genotypes in three mono-
phyletic groups; an association between the plasmid type, some
genotypes, and the nature of disease was observed (15). These
monophyletic groups supported the early RFLP groups and
placed groups I, II, and III in one monophyletic group; group
IV in the second monophyletic group; and group V in the third
monophyletic group. A comprehensive microarray-based
whole-genome comparison by Beare et al. confirmed the re-
latedness of RFLP-grouped isolates and added two more
genomic groups, VII and VIII (4). Differences in novel gene
contents and pseudogenes may be factors in the variations in
virulence seen among group I, IV, V, and VI isolates (5). It has
been shown in an intraperitoneal (i.p.)-challenge guinea pig
model that 101 organisms of the acute-disease-associated
group I isolate Nine Mile RSA493 (NM) caused fever, but 106
chronic-disease-associated group IV isolate MSU Goat Q177
(Priscilla) organisms were required to induce fever (36).
In opposition to the theory of genotype/pathotype correla-
tion, Stein and Raoult evaluated 28 human isolates and found
that isolates bearing the QpH1 plasmid were present in both
acute and chronic Q fever patients in France and that isolates
without the QpH1 plasmid were able to cause acute disease
(46). QpH1 plasmid-containing isolates have also been isolated
from chronic-endocarditis patients (50). Several groups have
speculated that host factors are primarily responsible for the
outcome of infection with C. burnetii. Individual differences in
immune function lead to varying sensitivity to infection and
disease development. In this model, acute and chronic disease
could be caused by organisms from the same isolate group, and
chronic disease could develop because of compromised resis-
tance of the host rather than as a consequence of a specific
property of the pathogen. For example, human immunodefi-
ciency virus infection is a risk factor for the development of
chronic Q fever endocarditis (9, 29). Deficiencies in the host-
specific cell-mediated immune response in Q fever patients
have been associated with the suppression of monocyte and
macrophage activities (25), and monocytes from chronic-Q
fever patients have been shown to be defective in phagosome
maturation and to have impaired C. burnetii-killing potential,
regulated in part by elevated interleukin-10 (IL-10) expression
(14). There is strong clinical evidence to support the role of
increased host production of IL-10 in the development of both
Q fever endocarditis and chronic fatigue syndrome (11, 12, 21,
39). A recent study suggested that chronic Q fever endocarditis
may be associated with atypical M2 polarization and stimula-
tion of bacterial replication (7), but the pathogenic process
that mediates this polarization was undefined.
The route of infection may also be an important determining
factor in the manifestation of acute and chronic Q fever. La
Scola et al. and Marrie et al. demonstrated that the route of
infection and the size of the inoculum affected clinical illness
and pathology associated with infection in mouse and guinea
pig models (26, 33). Differences in the geographic distributions
of the diseases have also been noted (32); in Nova Scotia, for
example, the primary manifestation of acute Q fever is pneu-
monia (34), but in France it is hepatitis, possibly due to inges-
tion of raw milk and unpasteurized cheeses (51).
The pathogenicity of C. burnetii has been evaluated using
guinea pigs, mice, and chicken embryos. Febrile response,
splenomegaly, and mortality in guinea pigs; splenomegaly and
mortality in mice; and mortality in chicken embryos are indi-
cators of virulence for C. burnetii. The establishment of an
aerosol model of C. burnetii infection in guinea pigs (43) pro-
vides a relevant model in which to test isolate virulence. Ad-
ditionally, severe combined immunodeficient (SCID) mice are
highly sensitive to the C. burnetii prototype (NM isolate) (1),
and the 50% lethal dose (LD50) of NM in SCID mice was at
least 108 times less than in wild type mice. We speculated that
with these highly sensitive rodent models it may be possible to
observe intra- and intergroup pathogenicity differences of C.
burnetii isolates. To confirm whether SCID mice could be used
to model isolate-specific virulence, we gave multiple infectious
doses of a group IV Q fever isolate to immune-competent
CB-17 and SCID mice (on the same background) to compare
them with previously reported group I isolate (NM) infections
(1). Eight isolates from four genomic groups (Table 1) were
then evaluated for the ability to cause acute disease in SCID
mouse i.p.-challenge and guinea pig aerosol challenge models.
We hypothesized that isolates within the same genotypic group
would cause similar diseases and that there would be a distinct
difference in disease manifestations between isolate groups.
Finally, we evaluated the potential of a vaccine composed of
one C. burnetii isolate to protect guinea pigs against infection
with an isolate from another group, since cross-protection be-
tween disparate isolate groups is a further indication of anti-
genic relatedness.
MATERIALS AND METHODS
Animals. The female 6- to 7-week-old CB-17/Icr-scid/scid (SCID) and wild-
type CB-17/Icr/ (CB-17) mice used in Japan were purchased from Japan
TABLE 1. Isolates evaluated for virulence
Genomic
group Isolate
Notation in
this study
Original source
Sample Yr Location Disease
I Nine Mile RSA493 NM Tick 1935 Montana, US NAa (acute; flu-like in humans)
African RSA334 African Human blood 1949 Central Africa Acute; Congolese Red Fever
Ohio 314 RSA270 Ohio Cow’s milk 1956 Ohio, US Persistent
IV MSU Goat Q177 Priscilla Goat Cotyledon 1980 Montana, US Abortion
P Q173 P Human heart valve 1979 California, US Endocarditis
V G Q212 G Human heart valve 1981 Nova Scotia, Canada Endocarditis
S Q217 S Human liver biopsy
specimen
1981 Montana, US Hepatitis
VI Dugway 5J108-111 Dugway Rodents 1958 Utah, US NA
a NA, not applicable.
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CLEA (Tokyo, Japan); A/J mice were purchased from Japan SLC (Shizuoka,
Japan). A/J mice were used because they are considered more susceptible to C.
burnetii than other inbred mouse strains (45). The female 6- to 8-week-old SCID
and wild-type CB-17 mice used in the United States were purchased from
Taconic (Hudson, NY). Female Hartley guinea pigs weighing approximately 350
to 450 g were purchased from Charles River Laboratories (Wilmington, MA).
All infected animals were housed in approved animal biosafety level 3 facili-
ties, and immunodeficient mice were housed under sterile conditions. All ani-
mals used in this study were acclimated to the facility and assessment procedures
during the week prior to infection to decrease stress-related abnormalities. An-
imal health was assessed daily by a veterinarian.
Mouse experiments performed in Japan adhered to the guidelines for animal
experiments at Gifu University. The Texas A&M University Laboratory Animal
Care Committee reviewed and approved the mouse and guinea pig research at
Texas A&M University, and experiments were carried out in AAALAC-ap-
proved facilities in accordance with university and federal regulations.
C. burnetii. Eight C. burnetii isolates from four genomic groups (Table 1) were
used. For the initial dose-effect experiment in Japan, C. burnetii MSU Goat Q177
(Priscilla), obtained from J. Kazar, Institute of Virology, Brastislava, Slovakia,
was maintained in mice by passage in spleen homogenates at Gifu University.
The spleen homogenates were stored at 80°C until they were used. The ab-
sence of contamination with other pathogens was confirmed by direct staining
(Gime´nez and Gram staining), detection of Mycoplasma DNA using a PCR
Mycoplasma detection set (Takara, Shiga, Japan), and inoculation of the spleen
homogenate into cell culture and SCID mice (independent experimental infec-
tion from the study described here). The bacterial dose was evaluated as the 50%
tissue culture infectious dose (TCID50) in BGM cells (buffalo green monkey
fibroblasts), the 50% infectious dose (ID50) in CB-17 mice, and the LD50 in
SCID mice. The TCID50 was determined by detecting the bacteria 6 days after
infection using immunofluorescence staining with anti-C. burnetii rabbit anti-
serum. The ID50 was determined by detecting seroconversion (immunoglobulin
G [IgG], 1:16) using indirect microimmunofluorescence. The LD50 was deter-
mined as reported previously (1).
For all subsequent experiments, all of the C. burnetii isolates were maintained
at the Texas A&M Health Science Center. The C. burnetii isolates were culti-
vated in embryonated chicken eggs, purified by gradient centrifugation as pre-
viously reported (19, 44, 53), and stored at 80°C until they were used. The
absence of contamination by other pathogens was confirmed as described above.
C. burnetii was quantified by optical density (OD) (53), direct viable-particle
count using the Live/Dead BacLight Bacterial Viability Kit (Molecular Probes,
Eugene, OR), and quantitative real-time PCR (qPCR) using primers amplifying
the com1 gene (8) (see Table S1 in the supplemental material). The bacterial
dose used for mouse infections was determined by qPCR; guinea pig doses were
calculated using the OD.
Experimental infection in mice. (i) Dose/effect experiment with the Priscilla
isolate. Six mice per group were used for the dose/effect experiment. SCID,
CB-17, and A/J mice were inoculated i.p. with serial 10-fold dilutions of Priscilla
(102 to 107 TCID50 per animal) or sterile phosphate-buffered saline (PBS)
(sham infection). SCID mice were observed for 112 days (16 weeks), and CB-17
and A/J mice were observed for 30 days.
(ii) Genomic group comparison. Four mice per group were used for the
genomic group comparison. Each of eight C. burnetii isolates described in Table
1 (105 genome copies/animal) or PBS was administered i.p. to SCID and CB-17
mice. Two independent infections were performed, and the mice were observed
for 28 days (for all of the C. burnetii isolates in SCID and CB-17 mice) or until
death (for four representative C. burnetii isolates in SCID mice).
Clinical signs were evaluated every 2 days by visual observation (ruffled fur,
hunched-back appearance, and lethargy) and body weight measurement. Body
weight changes were evaluated using a body weight index (BWI) derived as
follows: BWI  relative body weight/mean relative body weight of the control
group; relative body weight body weight on day “x” of infection/body weight on
the day of infection. Cachexia was diagnosed when a mouse was lethargic and
had a BWI of less than 0.85. At necropsy, the spleen weight was measured as an
indicator of C. burnetii infection (54), and tissues were collected. To quantify the
growth of C. burnetii, DNA was extracted from spleen tissue and C. burnetii com1
gene copies were detected by qPCR as previously described (8). The heart, lung,
liver, spleen, kidney, and femur were formalin fixed, embedded in paraffin, sliced,
and then prepared by hematoxylin-eosin staining and immunocytochemistry, as
described previously (1, 8), to evaluate histopathologic changes and bacterial
distribution in tissues. The degree of inflammation present in each tissue sample
was scored numerically by the following system: 0, none; 1, mild; 2, moderate; 3,
marked; 4, severe. IgG titers for phase I and II C. burnetii in the sera of CB-17
mice were measured by microimmunofluorescence as described elsewhere (1).
For cytokine assays, blood was collected from the lateral saphenous vein at 3, 7,
10, 14, and 21 days postinfection (p.i.) and via cardiac puncture at 28 days p.i.
after euthanasia, and the group pooled sera were stored at80°C until they were
used. Sixteen cytokines (IL-1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-12p40,
IL-12p70, IL-10, granulocyte-macrophage colony-stimulating factor, gamma in-
terferon [IFN-], KC, macrophage inflammatory protein 1 [MIP-1], RANTES,
and tumor necrosis factor alpha [TNF-]) were measured using the Bio-Plex
cytokine assay system (Bio-Rad, Hercules, CA) following the manufacturer’s pro-
tocol. The cytokine quantification assay was performed in duplicate for each
sample. The cytokine levels of infected sera were evaluated as the induction
values compared to the values of uninfected sera.
Experimental infection in guinea pigs. A chamber specially designed to deliver
droplet nuclei directly to the alveolar spaces (College of Engineering Shops,
University of Wisconsin, Madison), allowing the infection of multiple guinea pigs
simultaneously and ensuring uniform infection within each challenge group (35,
43, 52), was used for all guinea pig infection studies. (i) Three guinea pigs per
group were infected with low (102), mid-level (104), or high (106) doses of one of
the phase I C. burnetii isolates described in Table 1. Four negative control
animals were sham infected with sterile PBS. Body weight, rectal temperature,
and behavioral attitude were recorded, along with any abnormalities noted on
thoracic auscultation and abdominal palpation. A rectal temperature of 39.5°C
was defined as fever. The guinea pigs were observed for 28 days p.i. The spleens
and livers were weighed at necropsy. Tissues were collected and formalin fixed
for histopathologic evaluation. Serum was obtained from each animal for sero-
logic testing. (ii) In a separate experiment, three guinea pigs per group were
exposed to PBS or 2  106 particle equivalents of NM, P, G, or Dugway. Daily
assessment of these animals was performed as described above, and the organs
were weighed at necropsy 14 days p.i. to detect splenomegaly and/or hepato-
megaly. (iii) In the heterologous-protection study, guinea pigs were vaccinated
twice with 40 	g of formalin-inactivated group I (NM) or group V (S) C. burnetii
in Freund’s incomplete adjuvant or with adjuvant alone, with 2-week intervals
between the vaccinations and infection. The animals were then infected with high
doses of either NM or S. Three animals per group were separated into the
following six groups: (a) nonvaccinated, NM infected; (b) nonvaccinated, S
infected; (c) NM vaccinated, NM infected; (d) S vaccinated, S infected; (e) NM
vaccinated, S infected; and (f) S vaccinated, NM infected. The guinea pigs were
monitored for 14 days p.i. for development of fever and other clinical signs of
illness.
Histopathologic samples were prepared by hematoxylin and eosin staining or
by immunohistochemistry using a Vectastain ABC kit and a Vector NovaRed
substrate kit (Vector Laboratories, Burlingame, CA) and in-house-generated
rabbit anti-C. burnetii NM (3) and by counterstaining them with hematoxylin. All
slides were evaluated in a blinded fashion. Serum samples collected at necropsy
were tested by enzyme-linked immunosorbent assay for IgG titers against phase
I C. burnetii NM antigen as previously described (43). Sera from uninfected
guinea pigs were used as negative controls.
Statistical analyses. The results were expressed as means for each group and
were compared using one- and two-way analysis of variance or Student’s t test, as
appropriate. Differences were considered significant at a P value of 
0.05.
RESULTS
C. burnetii Priscilla is infective and exhibits delayed viru-
lence in SCID mice. A detailed analysis of dose-effect in an
immunocompromised-mouse model supported the previous
study by Moos and Hackstadt that evaluated the ability of the
Priscilla isolate to cause fever in i.p.-challenged guinea pigs
(36). The infectious titer of the Priscilla isolate in the splenic
homogenate used for the multiple-dose infection was 2  104
TCID50/ml in BGM cells, 2 10
9.3 ID50/ml in CB-17 mice, and
2  1010 LD50/ml in SCID mice (1 TCID50 corresponded to
105.3 ID50 in CB-17 mice and to 10
6 LD50 in SCID mice). The
LD50 in CB-17 mice could not be determined because no
CB-17 mice died from any infectious dose used in this study,
and the ID50 in SCID mice could not be determined due to
lack of antibody production. The ID50 in CB-17 mice and the
LD50 in SCID mice were similar, suggesting that SCID mice
could be lethally infected with very few viable organisms.
Multiple-dose infection of SCID mice with the Priscilla iso-
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late resulted in slow, progressive, and long-term-persistent dis-
ease. Clinical signs included ruffled fur, extremely distended
abdomens, and death. Body weight loss, inactivity, and ca-
chexia were not observed until a few days prior to death.
Survival time ranged from 55 to 109 days p.i. Progression of
clinical signs and survival times were dose dependent, with
shorter times corresponding to higher infectious doses (see
Table S2 in the supplemental material). Similar lesions were
found in all of the SCID mice that died, most notably severe
hepatosplenomegaly, and all organs had cellular infiltration,
primarily macrophages containing bacteria. The severity of the
lesions in infected SCID mice was not dependent on the C.
burnetii challenge dose.
On the other hand, CB-17 and A/J mice displayed transitory
clinical signs only after infection with the highest dose of
Priscilla. Both mouse strains showed ruffled fur from 4 to 13
days p.i., but only A/J mice demonstrated transient body
weight loss (data not shown). No other clinical signs were
observed. At 28 days p.i., CB-17 and A/J mice had mild spleno-
megaly and seroconversion as evidence of infection (data not
shown). Small granulomas were present in the spleen and liver,
but bacterial antigen was not detectable by immunohistochem-
istry.
Genomic-group-specific virulence in mice. It was important
to establish whether the results of infection seen with the
Priscilla isolate and those previously noted with the NM isolate
were genomic group specific (24). To determine this, the
pathogenicities of multiple isolates were compared by deliver-
ing a single dose of eight C. burnetii isolates from four genomic
groups (Table 1) to mice by i.p. injection. The infections were
initially compared in SCID and CB-17 mice sacrificed at 28
days p.i.
All C. burnetii isolates caused disease in SCID mice, with
various clinical courses. There was no mortality during the
28-day infection period. Clinical signs, including significant
body weight loss (P 
 0.05) and cachexia, summarized in Fig.
1A and in Fig. S1A in the supplemental material, were most
apparent in mice infected with group I isolates, followed by
those given group V, IV, and VI isolates. In CB-17 mice, only
mild transient disease was noted, with minimal loss of body
weight, in response to all isolates and noticeably ruffled fur
with group I isolate infection (Fig. 1B).
Splenomegaly in response to infection was more severe in
SCID than in CB-17 mice (Fig. 2A). The number of bacteria in
the spleens was determined by qPCR (Fig. 2B), and consis-
tently higher numbers of com1 genes were detected in SCID
than in CB-17 mice. SCID mice showed phylogenetic-group-
characteristic spleen size and growth of bacteria. Splenomegaly
was greatest in SCID mice with mild clinical disease infected
with bacteria from groups IV and VI. However, the number of
organisms in the spleen was greater in mice with severe clinical
disease following infection with phylogenetic groups I and V.
In CB-17 mice, splenic enlargement and numbers of bacteria
increased with the severity of clinical disease. CB-17 mice
displayed differences between infection with the C. burnetii
isolates that caused acute disease (phylogenetic group I) and
infection with the C. burnetii isolates that caused chronic dis-
ease (phylogenetic groups IV and V), but there was no differ-
ence between groups infected with isolates that caused chronic
disease. All infected mice developed significant splenomegaly,
FIG. 1. Average body weight changes in SCID mice (A) and CB-17 mice (B) infected with C. burnetii isolates during 28 days of infection. Body
weights were significantly lower in SCID mice throughout the infection period and transiently in CB-17 mice infected with all isolates except
Priscilla compared to PBS-injected controls (P 
 0.05).
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but mice infected with group IV, V, and VI isolates had sig-
nificantly fewer splenic bacteria than mice infected with group
I isolates (P 
 0.05).
Evaluation of histopathology at 28 days p.i. revealed more
lesions in SCID mice than in CB-17 mice (see Table S3 in the
supplemental material). SCID mice showed histopathologic
changes in all organs investigated. Group I isolates caused the
most inflammation, followed by groups V, IV, and VI. The
inflammatory-cell populations were similar in all groups and
consisted of few neutrophils and numerous macrophages con-
taining abundant intracytoplasmic bacteria. C. burnetii antigen
was diffusely distributed in all organs examined. CB-17 mice
had mild histopathologic changes in some organs, but even in
the tissues with an inflammatory response, C. burnetii antigen
was rarely detected.
Circulating cytokines are altered in C. burnetii-infected
CB-17 mice. The variations in pathology and inflammation
associated with these isolate group infections suggest differ-
ences in the immune responses. To expand on this observation,
the serum levels of 16 cytokines and chemokines were mea-
sured. In CB-17 mice, serum cytokine levels differed between
mice infected with group I isolates and those given isolates
from other groups. Group I isolates induced persistently high
cytokine secretion throughout the 28-day experiment; group
IV and V isolates caused moderate cytokine secretion at the
peak of clinical disease (7 to 14 days p.i.) (Fig. 3). After 14 days
p.i., group I isolates induced higher secretion of IL-3, IL-4,
IL-6, IL-10, IL-12p40, IL-12p70, IFN-, TNF-, MIP-1, and
RANTES than other groups. The KC and granulocyte-mac-
rophage colony-stimulating factor levels of mice infected with
group I isolates were higher than those in mice infected with
other groups prior to 14 days p.i. Serum IL-1, IL-1, IL-2,
and IL-5 levels and eotaxin secretion were not increased dur-
ing the infection period (data not shown).
Lethal potentials of all genomic groups in SCID mice. The
lethal potentials of representative isolates from each phyloge-
netic group were investigated in SCID mice, and it was deter-
mined that all of the isolates evaluated could eventually lead to
clinical illness and death in the immunodeficient model (see
Fig. S1B in the supplemental material). Isolates that caused a
long period of cachexia led to severe body weight loss in in-
fected mice (see Fig. S2 in the supplemental material). A
group I isolate (NM) induced the earliest and longest period of
cachexia and, correspondingly, the most severe body weight
loss. Mice infected with isolates from groups V (G) and VI
(Dugway) had similar survival times, but those given group V
isolates had longer periods of cachexia and more severe body
weight loss than group VI-infected mice. Infection with group
IV isolates (Priscilla and P) resulted in the shortest period of
cachexia, and body weight loss was not observed until the
terminal stage of infection. The survival time was shortest in
mice challenged with group I isolates (32.0  0.8 days), fol-
lowed by those infected with groups V (36.0  0.0 days), VI
(35.5  1.0 days), and IV (47.5  0.6 days for P and 77.3  2.8
days for Priscilla). The probable cause of death was multiple-
organ failure due to massive systemic infection.
The pathological changes in SCID mice at mortality were
more advanced than those observed at 28 days p.i. (data not
shown). The severity of inflammatory changes in the liver and
spleen was similar in all groups of infected mice, but animals
given group I isolates exhibited a greater degree of inflamma-
tion in the heart and lungs than those given group IV, V, and
VI isolates. The extent of splenomegaly changed with survival
time; however, the numbers of bacteria in the spleen were
similar in all groups, suggesting that the number of bacteria
(1010 genome copies/spleen) detected is the saturation point in
SCID mice. C. burnetii antigen was diffusely distributed in all
tissue sections.
Genomic-group-specific outcome of acute Q fever pneumo-
nia in the guinea pig aerosol model. Aerosol challenge in the
guinea pig provides a physiologically relevant model that sim-
ulates both the natural route of infection and common clinical
presentations associated with human acute Q fever, making
this a choice model for evaluating the comparative levels of
virulence of different C. burnetii isolates, and thus, it was used
in the logical progression of experiments after different levels
of virulence were observed in mouse models of infection.
Guinea pigs challenged with group I and V isolates developed
significant fever in response to infection (P 
 0.01), whereas
those given isolates from groups IV and VI were afebrile even
at the highest challenge dose (Fig. 4).
Fever response, weight loss, and other clinical signs dis-
played a dose-dependent relationship in guinea pigs infected
with the group I C. burnetii isolates African and Ohio, as has
been described for the reference isolate in this group, NM (43).
All animals that received African or Ohio organisms at a high
FIG. 2. Splenomegaly (A) and splenic bacterial loads (B) in mice at
28 days p.i. (A) All infected animals developed significant splenomeg-
aly compared to controls, and infected SCID mice had significantly
larger spleens than CB-17 mice (P 
 0.05). (B) Mice infected with
group IV, V, and VI isolates had significantly fewer bacteria than those
infected with group I isolates (P 
 0.05). *, P 
 0.05. The error bars
indicate standard deviations.
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dose died within 7 to 9 days p.i., as did two of three that
received NM; lower infectious doses were not lethal. Gross
lung consolidation and overall lack of normal body fat were
noted on necropsy at 7 to 9 days p.i. in guinea pigs infected
with the highest dose of organisms. Histologically, these ani-
mals had severe panleukocytic bronchointerstitial pneumonia
with bronchial and alveolar exudates. Lung tissues from the
surviving NM-infected guinea pig and those given the mid-level
dose of group I organisms were evaluated at 28 days p.i. for
comparison to animals infected with other isolates evaluated at
this time, and they exhibited moderate multifocal lymphohis-
tiocytic pneumonia with granuloma formation.
No significant fever or other overt clinical signs were noted
in guinea pigs infected with group IV isolates. Mild lympho-
histiocytic pneumonia was seen histologically at 28 days p.i. in
animals given the highest dose of organisms.
Group V isolate-infected guinea pigs all developed fever
when given the highest challenge dose, and dose-dependent
temperature increases and other clinical signs were again
noted, with no fever development, in those animals receiving
the lowest dose of organism. Though auscultation confirmed
respiratory compromise, none of the infections were lethal. At
28 days p.i., the lungs had mild to moderate lymphohistiocytic
interstitial pneumonia and a few small granulomas.
No major clinical or pathological changes were noted in
guinea pigs infected with the group VI isolate or in negative
control animals. Table S4 in the supplemental material com-
pares the severity of histopathologic changes in guinea pigs
infected with high doses of C. burnetii isolates from each group
at 28 days p.i. Immunohistochemistry confirmed the presence
of C. burnetii organisms, primarily in macrophages, in the
lungs, livers, and spleens of infected animals.
Experimental guinea pigs in all dose groups for each isolate
seroconverted by the time of euthanasia, with the exception
of animals infected with high doses of NM, African, and Ohio
necropsied at 1 week p.i. and low-dose Dugway-infected
guinea pigs. The degree of seroconversion was dose dependent
and varied among isolates (data not shown). No PBS-injected
control animals seroconverted.
Genomic-group-specific severity of hepatitis and spleno-
megaly in guinea pigs. The doughnut granulomas common in
human acute Q fever hepatitis (31) had not been previously
described in animals experimentally infected with C. burnetii
and were also not seen in the guinea pigs in this study. Mild
hepatitis and severe hepatic lipidosis were noted at death 7
days p.i. in guinea pigs challenged with high doses of group I
isolates, as had been previously reported for NM aerosol-
infected guinea pigs (43). Tissue sections from the remaining
NM-infected guinea pig and those infected with mid-level
doses of the group I organisms were evaluated for comparison
with animals infected with other isolates at 28 days p.i. and
revealed vacuolization and degeneration of centrilobular hepa-
tocytes, lymphocyte infiltration in periportal regions, and mul-
tiple small granulomas.
Group IV-infected guinea pigs also had periportal lympho-
cytic infiltration, as well as multiple granulomas of various
sizes. The granulomas in Priscilla- and P-infected guinea pigs
were more defined, with more histiocytic involvement than was
FIG. 3. Mean circulating cytokine levels in response to infection in CB-17 mice with different C. burnetii isolates. Isolates from genomic group
I induced persistently high cytokine secretion with increased levels of IL-6, TNF-, IL-12p40, IL-12p70, IFN-, IL-3, IL-4, IL-10, MIP-1, and
RANTES compared with other genogroups (P 
 0.05). }, PBS; , NM; ‚, African; , Ohio; F, Priscilla; }, P; f, G; Œ, S; E, Dugway.
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seen in guinea pigs infected with group I isolates. Subjectively,
of all animals necropsied from each isolate group, hepatic
granulomas from those infected with P were the greatest in size
and number.
The livers of guinea pigs infected with the group V isolates
G and S contained a few small granulomas and mild to mod-
erate infiltration of lymphocytes along portal tracts. The he-
patic changes observed in guinea pigs infected with group V
isolates suggested that isolates from this group are less hepa-
tovirulent than group IV isolates but more so than group I
isolates.
No hepatic granulomas or other significant pathological
changes were noted in guinea pigs infected with the group VI
isolate Dugway. Liver weights did not vary significantly within
or between genomic groups.
There were no significant differences in spleen weights at 28
days p.i. within or between genomic or dose groups. Animals
infected with all isolates examined at 14 days p.i. (NM, P, G,
and Dugway) had significantly larger spleens than PBS-in-
jected control animals, and spleens from NM- and G-infected
guinea pigs were significantly larger (P 
 0.01 and P 
 0.05,
respectively) than those of P- and Dugway-infected animals
(see Fig. S3 in the supplemental material). Pathological find-
ings included multiple small granulomas in the spleens of
group I-infected guinea pigs; fewer small granulomas were
occasionally noted in animals infected with group IV and V
isolates.
Heterologous protection of cross-vaccination and challenge
in guinea pigs. The infection studies described here illustrate
that there is pathotype diversity between C. burnetii isolates
from different genogroups, and they are consistent with phy-
logenetic studies cataloging distinct gene contents (4). We
therefore strove to determine whether this diversity was great
enough to affect the ability of vaccines to protect against in-
fection. Guinea pigs were given group I (NM) or group IV (S)
vaccine and cross-challenged to evaluate potential heterolo-
gous protection against high-dose infection. Nonvaccinated
guinea pigs developed a noticeable fever response by day 5 p.i.,
FIG. 4. Fever responses of guinea pigs to infection with high doses of C. burnetii isolates. The mean daily temperatures  standard errors of
the mean (n 3) of animals infected with 2 106 bacteria of each C. burnetii isolate. Temperatures of39.5°C (black lines) were considered fever.
The arrows indicate days on which death occurred in NM-, African-, and Ohio-infected groups.
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and infection was lethal in three of three NM- and one of three
S-challenged animals. Guinea pigs vaccinated with either for-
malin-killed NM or S were completely protected against fever
development and death when challenged with either NM or S
(Fig. 5).
DISCUSSION
The potential for genomic-group-specific pathogenicity of C.
burnetii was evaluated using immunocompetent mice and
guinea pigs and immunodeficient mice. The hypotheses that
isolates belonging to the same genomic group would cause
similar disease and that there would be distinctions in disease
manifestations between isolate groups were supported by the
findings presented here.
A detailed analysis of the Priscilla isolate dose-effect in
SCID mice revealed differences in virulence of C. burnetii
isolates. Disease development after Priscilla infection was pro-
gressive but slower than the development of the disease caused
by NM previously reported in SCID mice (1); the survival time
of SCID mice infected with Priscilla was longer with the same
LD50. This result supports the previous study by Moos and
Hackstadt that evaluated the lesser ability of the Priscilla iso-
late to cause fever in i.p.-challenged guinea pigs (36). Interest-
ingly, the mice infected with Priscilla did not exhibit cachexia
until the terminal stages of infection, when they had extremely
severe hepatosplenomegaly. Although the disease caused by
Priscilla was milder than that associated with NM, all mice that
developed clinical illness died. This result confirms the high
infectivity and lethal potential of C. burnetii, which is not re-
stricted to isolates that cause acute disease, and suggests that
the SCID mouse model can be useful for evaluation of C.
burnetii virulence.
The virulence of C. burnetii isolates tested in SCID mice was
determined to be genomic group specific. Acute-Q fever-asso-
ciated group I isolates caused the most rapidly progressing
disease and the most severe pathological changes. Groups IV
and V, isolates associated with chronic Q fever, caused a
slower progression of disease. Overall, pathological changes in
mice infected with group IV and V isolates were milder than
those of group I-infected mice. The number of bacteria in the
spleen at 28 days p.i. was greater in mice with severe disease
from infection with group I isolates; however, the bacterial
loads at the time of death were similar in all infected mice. This
suggests that the rate of proliferation of C. burnetii in vivo may
be virulence related. An in vitro comparison of infection in
L929 cells using NM, Priscilla, and S isolates showed that all of
the isolates could persistently infect, but Priscilla required a
greater period of time to establish an infection (42), and it has
been shown that inclusion-forming units produced by NM and
Priscilla isolates were similar in Vero cells (36). However,
because of developmental differences in clinical signs and
pathological changes, the replication rate does not seem to be
the only virulence factor involved, since clinical signs would
then be similar with differences only in disease progression. At
both time points, 28 days p.i. and the time of death due to
infection, heart and lung lesions caused by group IV, V, and VI
isolates were milder than those produced by infection with
group I isolates. This observation seems to conflict with the
hypothesis that isolates from chronic disease cause chronic Q
fever, including heart disease. However, our observation is
consistent with the report that isolates from heart lesions of
FIG. 5. Heterologous vaccination and challenge in guinea pigs. Shown are average daily temperatures of animals vaccinated with NM (dashed
and dotted line), S (dashed line), or adjuvant alone (solid line) and challenged with high doses of NM (}) or S (). Temperatures of 39.5°C
were considered fever.
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chronic-Q fever patients have genetic characteristics similar to
those of isolates from acute disease (46). The hypothesis that
isolates from acute disease do not cause endocarditis has been
supported by two other research groups (17, 24). The correla-
tion between virulence and phylogeny has been controversial
because of a lack of comprehensive studies. One study de-
tected genes specific to isolates from acute disease in isolates
from chronic Q fever patients and concluded that the isolates
were not disease specific (46). The isolates used in the study
were isolated by cell culture, and although the cell culture
system is highly effective for isolation, isolates from acute dis-
ease are known to infect cultured cells more efficiently than
isolates from chronic disease, so there remains a potential that
the study collected only cell culture-adapted isolates. Several in
vivo studies have reported isolate-specific virulence using
guinea pig and mouse models (17, 24, 36); however, the num-
ber of isolates used in these studies was limited, making it
difficult to conclude that there was genomic-group-specific vir-
ulence. The present study using eight isolates from four phy-
logenetic groups strongly supports the variation in virulence
among C. burnetii isolate groups.
In the absence of functional T and B cells, cytokine profiles
showed no group-specific differences. In immunocompetent
mice, group I isolates caused a stronger immune response with
high levels of multiple cytokines over a longer time than other
groups. Interestingly, Dugway (group VI) induced the least
change in CB-17 mice. The inflammatory-cytokine changes in
immunocompetent mice in this study were similar to those in
humans with acute Q fever (10): TNF- and IL-6 were upregu-
lated, but IL-1 was not. IFN- increased in CB-17 mice in-
fected with group I isolates, and it is associated with the control
of bacterial growth, stimulates phagosome-lysosome fusion,
and may enable monocytes/macrophages to kill C. burnetii (13,
14). A difference in vacuole formation between isolates has
also been shown, with NM and S developing within single large
vacuoles while Priscilla occupied several smaller vacuoles per
cell (18). This in vitro study suggested a difference in isolate
ecology within host cells, which may be correlated with their
virulence in vivo.
The ability to cause fever and respiratory illness was isolate
and dose dependent in the guinea pig aerosol challenge model,
with isolates from groups I and V causing disease consistent
with human acute Q fever. Isolates within the same genomic
group produced similar clinical illnesses, strongly supporting
the mouse experiments demonstrating that genomic differ-
ences in the bacterial isolates do play a role in virulence. It was
shown here that isolates associated with chronic disease, G and
S, have the ability to cause acute disease in the guinea pig
model. Our study confirmed and expanded the observations of
Kazar et al. that the virulence of NM and S isolates was greater
than that of Priscilla.
Lesny et al. compared the cross-immunity of whole-cell and
soluble Q fever vaccines made from phase I NM, S, Priscilla,
and Luga isolates. They found that vaccines from NM and
Priscilla afforded a higher degree of protection than S and
Luga vaccines and that whole-cell vaccines were more effective
than soluble vaccines (28). In the guinea pig challenge study
presented here, killed whole-cell vaccines made from isolates
differing in LPS banding pattern (16), plasmid type (44), and
genomic group (20), specifically isolates from groups I and V,
conferred heterologous protection against virulent high-dose
challenge in accordance with previous studies (28). This sug-
gests that although the manifestations of disease and genomic
contents differ among various isolate groups, the antigenic
properties of whole-cell vaccines are shared enough that cross-
protection is possible. Such information is valuable for the
design of new vaccines and could be of the utmost importance
in offering reliable protection in the event of an outbreak.
The differences in perceived infectious doses noted when
ODs, particle counts, and genome copy enumerations were
compared underline the importance of using multiple quanti-
tation methods to compare studies with earlier observations.
Some of the differences in disease manifestations seen in
guinea pigs in this study could be due to slight differences in
the infectious doses delivered. For instance, Priscilla and P
both induced hepatic changes, although guinea pigs infected
with P appeared to develop more severe lesions than those
infected with Priscilla, which had a lower infectious dose by
OD and qPCR. The difference in infectious dose as deter-
mined by the genome copy number could account for this
variation. However, G and S both caused fever, and although
guinea pigs infected with G did not attain the same degree of
febrile response as S-infected animals, quantitation by particle
count and real-time PCR showed infectious doses of S to be
over a log unit lower than those of G. It could be argued that
Priscilla-infected guinea pigs did not develop fever because
fewer bacteria were present in the aerosol challenge; however,
the group IV isolates did not induce fever at any of the chal-
lenge doses while group I isolates induced fever even at the
lowest dose. We believe that, despite the variation in the in-
fectious dose depending on the enumeration technique, the
significant differences noted among genotypic groups are valid.
Phase variation is the only well-characterized phenotypic
difference that is related to virulence in C. burnetii (50). Al-
though LPS may be a major virulence determinant, and isolate
LPS banding patterns have been correlated with acute or
chronic disease (16), other components alone or in association
with LPS may be responsible for differences in mortality in
SCID mice and fever development in aerosol-challenged
guinea pigs. It has been hypothesized that differences in the
lipid A component are responsible for the variations in viru-
lence, but lipid structural information indicates they are simi-
lar. The combination of a variety of factors expressed by phase
I bacteria likely governs the ability of C. burnetii to infect cells
and to maintain continuous growth within the phagolysosome.
Indeed, the combination of pathotype variation of disease in
infected guinea pigs and cross-protection of different isolates
suggests conserved predominant antigenic components with
virulence determinant specificity.
A recent report compared all open reading frames of NM
phase I to those of African, Ohio, P, G, S, and Dugway, among
others (4), and a majority of the open reading frames deleted
from NM in the other isolates were either hypothetical or
nonfunctional; however, a few were associated with assorted
cellular functions. Beare et al. compared the complete genome
sequences of NM, K, G, and Dugway and found distinct col-
lections of pseudogenes and unique gene contents that may
contribute to pathotype-specific virulence, including type II
and type IV secreted effector molecules (5). Integrating our in
vivo data with these molecular details, as well as with other in
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vitro studies, may reveal the critical virulence determinants of
C. burnetii and ultimately identify targets for vaccine and ther-
apeutic intervention.
Isolates of phase I C. burnetii have the potential to cause a
range of clinical signs, including fever, pneumonia, hepatitis,
and splenomegaly. Isolates from one human chronic-disease
group induced mild to moderate acute disease in the physio-
logically relevant guinea pig aerosol challenge model, while a
separate isolate group representing several chronic-disease iso-
lates caused no acute disease. All isolates examined were ca-
pable of producing disease in the immunocompromised SCID
mouse model, and genogroup-consistent trends were noted in
cytokine production in response to infection in the immuno-
competent-mouse model. In these studies, isolates within the
same genomic group caused similar pathological responses,
with a distinction in strain virulence between established geno-
groups, sustaining the theory that genetic differences in the
bacterial isolates affect their virulence.
ACKNOWLEDGMENTS
This work was supported by funding from NIH NIAID grants KO8
AI055664, U54 AI057156, and RO1 AI057768 and Science Research
Grant number 13460142 from the Ministry of Education, Science,
Sports and Culture of Japan.
We are grateful to Laura R. Hendrix for critical review of the
manuscript.
REFERENCES
1. Andoh, M., T. Naganawa, A. Hotta, T. Yamaguchi, H. Fukushi, T. Masegi,
and K. Hirai. 2003. SCID mouse model for lethal Q fever. Infect. Immun.
71:4717–4723.
2. Arricau-Bouvery, N., Y. Hauck, A. Bejaoui, D. Frangoulidis, C. C. Bodier, A.
Souriau, H. Meyer, H. Neubauer, A. Rodolakis, and G. Vergnaud. 2006.
Molecular characterization of Coxiella burnetii isolates by infrequent restric-
tion site-PCR and MLVA typing. BMC Microbiol. 6:38.
3. Baumgartner, W., H. Dettinger, N. Schmeer, and E. Hoffmeister. 1988.
Evaluation of different fixatives and treatments for immunohistochemical
demonstration of Coxiella burnetti in paraffin-embedded tissues. J. Clin.
Microbiol. 26:2044–2047.
4. Beare, P. A., J. E. Samuel, D. Howe, K. Virtaneva, S. F. Porcella, and R. A.
Heinzen. 2006. Genetic diversity of the Q fever agent, Coxiella burnetii,
assessed by microarray-based whole-genome comparisons. J. Bacteriol. 188:
2309–2324.
5. Beare, P. A., N. Unsworth, M. Andoh, D. E. Voth, A. Omsland, S. D. Gilk,
K. P. Williams, B. W. Sobral, J. J. Kupko III, S. F. Porcella, J. E. Samuel,
and R. A. Heinzen. 2008. Comparative genomics reveal extensive transpo-
son-mediated genomic plasticity and diversity among potential effector pro-
teins within the genus Coxiella. Infect. Immun. 77:642–656.
6. Benenson, A. S., and W. D. Tigertt. 1956. Studies on Q fever in man. Trans.
Assoc. Am. Physicians 69:98–104.
7. Benoit, M., E. Ghigo, C. Capo, D. Raoult, and J. L. Mege. 2008. The uptake
of apoptotic cells drives Coxiella burnetii replication and macrophage polar-
ization: a model for Q fever endocarditis. PLoS Pathog. 4:e1000066.
8. Brennan, R. E., and J. E. Samuel. 2003. Evaluation of Coxiella burnetii
antibiotic susceptibilities by real-time PCR assay. J. Clin. Microbiol. 41:
1869–1874.
9. Brouqui, P. 1993. Chronic Q fever. Arch. Inern. Med. 153:642–648.
10. Capo, C., N. Amirayan, E. Ghigo, D. Raoult, and J. Mege. 1999. Circulating
cytokine balance and activation markers of leucocytes in Q fever. Clin. Exp.
Immunol. 115:120–123.
11. Capo, C., Y. Zaffran, F. Zugan, P. Houpikian, D. Raoult, and J. L. Mege.
1996. Production of interleukin-10 and transforming growth factor  by
peripheral blood mononuclear cells in Q fever endocarditis. Infect. Immun.
64:4143–4150.
12. Ghigo, E., C. Capo, D. Raoult, and J. L. Mege. 2001. Interleukin-10 stimu-
lates Coxiella burnetii replication in human monocytes through tumor necro-
sis factor down-modulation: role in microbicidal defect of Q fever. Infect.
Immun. 69:2345–2352.
13. Ghigo, E., C. Capo, C. H. Tung, D. Raoult, J. P. Gorvel, and J. L. Mege. 2002.
Coxiella burnetii survival in THP-1 monocytes involves the impairment of
phagosome maturation: IFN-gamma mediates its restoration and bacterial
killing. J. Immunol. 169:4488–4495.
14. Ghigo, E., A. Honstettre, C. Capo, J. P. Gorvel, D. Raoult, and J. L. Mege.
2004. Link between impaired maturation of phagosomes and defective Cox-
iella burnetii killing in patients with chronic Q fever. J. Infect. Dis. 190:1767–
1772.
15. Glazunova, O., V. Roux, O. Freylikman, Z. Sekeyova, G. Fournous, J. Tyc-
zka, N. Tokarevich, E. Kovacava, T. J. Marrie, and D. Raoult. 2005. Coxiella
burnetii genotyping. Emerg. Infect. Dis. 11:1211–1217.
16. Hackstadt, T. 1986. Antigenic variation in the phase I lipopolysaccaride of
Coxiella burnetii isolates. Infect. Immun. 52:337–340.
17. Hackstadt, T. 1990. The role of lipopolysaccharides in the virulence of
Coxiella burnetii. Ann. N. Y. Acad. Sci. 590:27–32.
18. Hechemy, K. E., M. McKee, M. Marko, W. A. Samsonoff, M. Roman, and O.
Baca. 1993. Three-dimensional reconstruction of Coxiella burnetii-infected
L929 cells by high-voltage electron microscopy. Infect. Immun. 61:4485–
4488.
19. Hendrix, L., and L. P. Mallavia. 1984. Active transport of proline by Coxiella
burnetii. J. Gen. Microbiol. 130:2857–2863.
20. Hendrix, L. R., J. E. Samuel, and L. P. Mallavia. 1991. Differentiation of
Coxiella burnetii isolates by analysis of restriction-endonuclease-digested
DNA separated by SDS-PAGE. J. Gen. Microbiol. 137:269–276.
21. Honstettre, A., G. Imbert, E. Ghigo, F. Gouriet, C. Capo, D. Raoult, and J. L.
Mege. 2003. Dysregulation of cytokines in acute Q fever: role of interleu-
kin-10 and tumor necrosis factor in chronic evolution of Q fever. J. Infect.
Dis. 187:956–962.
22. Huebner, R. J., W. L. Jellison, and M. D. Beck. 1949. Q fever studies in
southern California. III. Effects of pasteurization on survival of Coxiella
burnetii in naturally infected milk. Public Health Rep. 64:499–511.
23. Jager, C., H. Willems, D. Thiele, and G. Baljer. 1998. Molecular character-
ization of Coxiella burnetii isolates. Epidemiol. Infect. 120:157–164.
24. Kazar, J., M. Lesny, P. Propper, D. Valkova, and R. Brezina. 1993. Com-
parison of virulence for guinea pigs and mice of different Coxiella burnetii
phase I strains. Acta Virol. 37:437–448.
25. Koster, F. T., J. C. Williams, and J. S. Goodwin. 1985. Cellular immunity in
Q fever: modulation of responsiveness by a suppressor T cell-monocyte
circuit. J. Immunol. 135:1067–1072.
26. La Scola, B., H. Lepidi, and D. Raoult. 1997. Pathologic changes during
acute Q fever: influence of the route of infection and inoculum size in
infected guinea pigs. Infect. Immun. 65:2443–2447.
27. Lennette, E. H., W. H. Clark, M. M. Abinanti, O. Brunetti, and J. M. Covert.
1952. Q fever studies. XIII. The effect of pasteurization on Coxiella burnetii
in naturally infected milk. Am. J. Hyg. 55:246–253.
28. Lesny, M., J. Kazar, P. Propper, and M. Lukacova. 1991. Virulence and
cross-immunity study on guinea pigs infected with different phase I Coxiella
burnetii strains, p. 666–673. In J. Kazar and D. Raoult (ed.), Rickettsiae and
rickettsial diseases. Publishing House of the Slovak Academy of Sciences,
Bratislava, Slovakia.
29. Madariaga, M. G., J. Pulvirenti, M. Sekosan, C. D. Paddock, and S. R. Zaki.
2004. Q fever endocarditis in HIV-infected patients. Emerg. Infect. Dis.
10:501–504.
30. Marrie, T. J. 1990. Acute Q fever, p. 125–160. In T. J. Marrie (ed.), Q fever,
vol. 1. The disease. CRC Press, Boca Raton, FL.
31. Marrie, T. J. 1990. Q fever hepatitis, p. 171–178. In T. J. Marrie (ed.), Q
fever, vol. 1. The disease. CRC Press, Boca Raton, FL.
32. Marrie, T. J. 2004. Q fever pneumonia. Curr. Opin. Infect. Dis. 17:137–142.
33. Marrie, T. J., A. Stein, D. Janigan, and D. Raoult. 1996. Route of infection
determines the clinical manifestations of acute Q fever. J. Infect. Dis. 173:
484–487.
34. Maurin, M., and D. Raoult. 1999. Q fever. Clin. Microbiol. Rev. 12:518–553.
35. McMurray, D. N. 1994. Guinea pig model of tuberculosis, p. 135–147. In
B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control.
American Society for Microbiology, Washington, DC.
36. Moos, A., and T. Hackstadt. 1987. Comparative virulence of intra- and
interstrain lipopolysaccharide variants of Coxiella burnetii in the guinea pig
model. Infect. Immun. 55:1144–1150.
37. Ormsbee, R. A. 1965. Q fever rickettsia, p. 1144–1160. In F. L. Horsfall and
I. Tamm (ed.), Viral and rickettsial diseases of man. J. B. Lippencott, Phil-
adelphia, PA.
38. Reference deleted.
39. Penttila, I. A., R. J. Harris, P. Storm, D. Haynes, D. A. Worswick, and B. P.
Marmion. 1998. Cytokine dysregulation in the post-Q-fever fatigue syn-
drome. QJM 91:549–560.
40. Raoult, D., and T. Marrie. 1995. Q Fever. Clin. Infect. Dis. 20:489–496.
41. Raoult, D., A. Raza, and T. J. Marrie. 1990. Q fever endocarditis and other
forms of chronic Q fever, p. 179–120. In T. J. Marrie (ed.), Q fever, vol. 1.
The disease. CRC Press, Boca Raton, FL.
42. Roman, M. J., H. A. Crissman, W. A. Samsonoff, K. E. Hechemy, and O. G.
Baca. 1991. Analysis of Coxiella burnetii isolates in cell culture and the
expression of parasite-specific antigens on the host membrane surface. Acta
Virol. 35:503–510.
43. Russell-Lodrigue, K. E., G. Q. Zhang, D. N. McMurray, and J. E. Samuel.
2006. Clinical and pathologic changes in a guinea pig aerosol challenge
model of acute Q fever. Infect. Immun. 74:6085–6091.
44. Samuel, J. E., M. E. Frazier, and L. P. Mallavia. 1985. Correlation of
VOL. 77, 2009 COXIELLA BURNETII ISOLATE VIRULENCE 5649
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
plasmid type and disease caused by Coxiella burnetii. Infect. Immun. 49:775–
779.
45. Scott, G. H., J. C. Williams, and E. H. Stephenson. 1987. Animal models in
Q fever: pathological responses of inbred mice to phase I Coxiella burnetii.
J. Gen. Microbiol. 133:691–700.
46. Stein, A., and D. Raoult. 1993. Lack of pathotype specific gene in human
Coxiella burnetii isolates. Microb. Pathog. 15:177–185.
47. Stoenner, H. G., R. Holdenried, D. Lackman, and J. S. Orsborn. 1959. The
occurrence of Coxiella burnetii, Brucella, and other pathogens among fauna
of the Great Salt Lake Desert in Utah. Am. J. Trop. Med. Hyg. 8:590–595.
48. Stoenner, H. G., and D. B. Lackman. 1960. The biologic properties of
Coxiella burnetii isolated from rodents collected in Utah. Am. J. Hyg.
71:45–51.
49. Svraka, S., R. Toman, L. Skultety, K. Slaba, and W. L. Homan. 2006.
Establishment of a genotyping scheme for Coxiella burnetii. FEMS Micro-
biol. Lett. 254:268–274.
50. Thiele, D., and H. Willems. 1994. Is plasmid based differentiation of Coxiella
burnetii in ‘acute’ and ‘chronic’ isolates still valid? Eur. J. Epidemiol. 10:427–434.
51. Tissot Dupont, H., D. Raoult, P. Brouqui, F. Janbon, D. Peyramond, P. J.
Weiller, C. Chicheportiche, M. Nezri, and R. Poirier. 1992. Epidemiologic
features and clinical presentation of acute Q fever in hospitalized patients:
323 French cases. Am. J. Med. 93:427–434.
52. Wiegeshaus, E. H., D. N. McMurray, A. A. Grover, G. E. Harding, and D. W.
Smith. 1970. Host-parasite relationships in experimental airborne tubercu-
losis. 3. Relevance of microbial enumeration to acquired resistance in guinea
pigs. Am. Rev. Respir. Dis. 102:422–429.
53. Williams, J. C., M. G. Peacock, and T. F. McCaul. 1981. Immunological and
biological characterization of Coxiella burnetii, phase I and phase II, sepa-
rated from host components. Infect. Immun. 32:840–851.
54. Zhang, G. Q., and J. E. Samuel. 2003. Identification and cloning poten-
tially protective antigens of Coxiella burnetii using sera from mice exper-
imentally infected with Nine Mile phase I. Ann. N. Y. Acad. Sci. 990:
510–520.
Editor: R. P. Morrison
5650 RUSSELL-LODRIGUE ET AL. INFECT. IMMUN.
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
